- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.03. | Enliven Therapeutics GAAP EPS of -$0.46 | 1 | Seeking Alpha | ||
| 13.03. | Enliven Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.03. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update | 555 | PR Newswire | Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues
Expected monotherapy and combination data from the ELVN-002 Phase 1... ► Artikel lesen | |
| 13.03. | Enliven Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 13.03. | Enliven Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.11.24 | Enliven Therapeutics GAAP EPS of -$0.48 beats by $0.02 | 2 | Seeking Alpha | ||
| 13.11.24 | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update | 235 | PR Newswire | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains... ► Artikel lesen | |
| 30.10.24 | Enliven Therapeutics gets Buy rating, $36 target from Jones Trading | 1 | Investing.com | ||
| ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.05.24 | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | 433 | GlobeNewswire (Europe) | Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients Strong balance... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,156 | +0,45 % | Valneva: US-Impfempfehlung mit Vorsichtsmaßnahme für IXCHIQ bleibt bestehen | Valneva erhält vom US-amerikanischen Beratungsgremium ACIP erneut eine Empfehlung für den Einsatz des Chikungunya-Impfstoffs IXCHIQ. Der Impfstoff soll weiterhin Personen ab 18 Jahren verabreicht werden... ► Artikel lesen | |
| BIOFRONTERA | 2,310 | 0,00 % | PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Biofrontera... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 35,000 | +1,74 % | Crispr Therapeutics Aktie: Verliert ihren Kurs? | Der Austritt des operativen Geschäftsführers beim Gentherapie-Unternehmen beunruhigt Investoren und wirft Fragen zur Projektkontinuität im wettbewerbsintensiven Biotech-Sektor auf. Die Finanzmärkte... ► Artikel lesen | |
| BLUEBIRD BIO | 3,660 | +0,55 % | bluebird bio Aktie: Welche Strategie verspricht Erfolg? | Carlyle Group und SK Capital Partners akquirieren Gentherapie-Entwickler bluebird bio. Der Börsenrückzug ermöglicht dem Unternehmen, fernab des Kapitalmarkts seine Strategie neu zu justieren. Die Finanzmärkte... ► Artikel lesen | |
| AFFIMED | 0,530 | -100,00 % | Affimed N.V.: Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,... ► Artikel lesen | |
| SORRENTO THERAPEUTICS | - | - | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 | US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,219 | +2,35 % | Fate Therapeutics, Inc.: Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) | - Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process - RMAT review by FDA included... ► Artikel lesen | |
| DENALI THERAPEUTICS | 13,415 | -1,36 % | Denali Therapeutics Aktie: FDA-Entscheidung beflügelt | Denali Therapeutics erhält Breakthrough-Status für Hunter-Syndrom-Medikament. Analysten sehen großes Potenzial und erhöhen Kursziele. Die Aktie des Biotech-Unternehmens Denali Therapeutics zeigt sich... ► Artikel lesen | |
| CELLECTIS | 1,416 | +0,71 % | Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal | ||
| AGIOS | 24,000 | -6,98 % | Agios Pharmaceuticals, Inc.: Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer | CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,018 | -2,96 % | Voyager Therapeutics, Inc.: Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD 2025 | - Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical... ► Artikel lesen | |
| UNIQURE | 12,805 | +2,24 % | UniQure stock holds $70 target, buoyed by FDA breakthrough nod | ||
| ENZO BIOCHEM | 0,452 | +8,13 % | Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction | Forms Special Committee of the Board to Lead Evaluation of Viable Options for Maximizing Shareholder Value Engages Independent Financial and Legal Advisors to Support Thorough Process Remains Committed... ► Artikel lesen | |
| SCILEX | 4,360 | 0,00 % | Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April ... | ||
| TECTONIC THERAPEUTIC | 22,380 | 0,00 % | Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure... ► Artikel lesen |
ENLIVEN THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 18,430 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENLIVEN THERAPEUTICS INC finden Sie auf Wallstreet Online.
